Merrill's buy rating for Alkermes unchanged

Alkermes, Inc. was kept at a buy rating by Merrill Lynch analyst Hari Sambasivam on news of the company's reported revenues of $51.5 million, including net collaborative profit from Vivitrol of $9.7 million. Revenues were consistent with Merrill's estimates of $45.8 million and $11.7 million of net collaborative profit. Alkermes reiterated financial guidance for 2007 including revenues of $200 million to $222 million and Vivitrol sales in the range of $35 million to $45 million. Shares of the Cambridge, Mass.-based biotechnology company were up 36 cents, or 2.22%, at $16.57, on volume of 1,237,183 shares versus the three-month running average of 1,113,960 shares. (Nasdaq: ALKS)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.